Andrew Cheng - Dec 10, 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: President and CEO, Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Stock symbol: AKRO
Transactions as of: Dec 10, 2024
Transactions value $: -$241,855
Form type: 4
Date filed: 12/12/2024, 08:24 PM
Previous filing: Dec 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Sale	-$242K	-7.86K	-1.3%	$30.79	598K	Dec 10, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.79 to $30.93, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.79 to $30.93, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.